Combined metformin and sitagliptin effect on expression levels of proteins involved in insulin resistance in adipose tissue of diabetic patients

Combined metformin and sitagliptin effect on expression levels of proteins involved in insulin resistance (IRS-1/PI3K/Akt/mTOR/GLUT4) in adipose tissue of diabetic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171018036870N2

Enrollment

Registered

2018-08-26

Start date

2018-02-04

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus. diabetes (mellitus)(nonobese)(obese): adult-onset maturity-onset nonketotic stable type II non-insulin-dependent diabetes of the young

Interventions

Intervention 1: Intervention group: We have two intervention groups: Group 1: This group only receive metformin for 3 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who have not yet taken medication and are recently diagnosed with a blood glucose test, the so-called New Case.

Exclusion criteria

Exclusion criteria: Diabetics who are taking medications, taking pills or taking insulin, have been eliminated.

Design outcomes

Primary

Measure	Time frame
Combined metformin and sitagliptin effect on expression levels of proteins involved in insulin resistance IRS-1/PI3K/Akt/mTOR/GLUT4. Timepoint: Measuring the proteins involved in insulin resistance at the beginning of the study (before metformin and citagliptin therapy) and in 90 days (3 months) of drug use (after treatment with metformin and sitagliptin). Method of measurement: How to measure these proteins using SDS-PAGE and Western blotting.	—

Measure

Time frame

Combined metformin and sitagliptin effect on expression levels of proteins involved in insulin resistance IRS-1/PI3K/Akt/mTOR/GLUT4. Timepoint: Measuring the proteins involved in insulin resistance at the beginning of the study (before metformin and citagliptin therapy) and in 90 days (3 months) of drug use (after treatment with metformin and sitagliptin). Method of measurement: How to measure these proteins using SDS-PAGE and Western blotting.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Didehdar

Yazd University of Medical Sciences

didehdar@zbmu.ac.ir+98 35 3820 3417

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026